Pharmaceuticals

Octapharma's $1.5 billion Rock Hill facility promises 1,500 high-paying jobs. But beyond the local boom, it signals a critical shift in securing America's medical supply chain.

A small logistics firm with big ambitions breaks ground in rural Alabama, promising a $500M biomanufacturing hub to help secure America's drug supply.

Clene Inc. heads to the Canaccord Growth Conference with promising ALS data and a clear regulatory path, but faces a critical test of investor confidence.

As Akebia Therapeutics preps its Q2 report, all eyes are on Vafseo's uptake, a declining Auryxia, and a costly R&D push into rare kidney diseases.

With a novel drug targeting an unaddressed cause of glaucoma, Qlaris Bio adds a seasoned expert to its board, signaling a pivotal push toward market entry.

Processa Pharmaceuticals acquires Vidya Therapeutics and its key asset, VT-7208, backed by a $200M financing that radically overhauls the company's strategy.

Qnovia secures a license for a novel peptide, D8, that kills superbugs differently. Can this university-born innovation turn the tide on antibiotic resistance?

Par Health's new ready-to-use Sugammadex syringe tackles medication errors and workflow delays, signaling a major shift in how essential medicines are delivered.

An FDA panel's nod to controversial peptides seems to validate Hydreight's long-term strategy. But a closer look reveals a long road and a deep data gap.

Shionogi launches XOCOVA, the first oral pill to prevent COVID after exposure. With a 67% efficacy rate and a $1,400 price tag, who will it protect?

A new study argues state-imposed price caps on drugs fail to lower patient costs, instead threatening the supply chain for our most vulnerable citizens.

By selling its mass cytometry unit and securing a $30M payout, Standard BioTools is fortifying its balance sheet for a transformative merger with Treeline.

Lantern Pharma's EMA-cleared trial for LP-184 uses a dual-biomarker strategy, targeting a multi-billion dollar market where patient options are scarce.

A new biotech, CORE Biomedicine, armed with Eisai's preclinical assets and a $21M Series A, aims to upend oncology by targeting cancer's 'lineage' identity.

Dasher Neuroscience completes Phase 2 enrollment for its AI-designed drug for MSA, a fatal disease with no cure, signaling a major step toward a first-in-class therapy.

NextPlat declares a strategic turnaround, but the real story is its complex model: blending high-margin healthcare with niche satellite tech. Can it deliver?

Two small firms just secured a patent until 2045 on a decades-old drug. It's a masterclass in strategy, revealing the future of pharmaceutical value.

With two blockbuster cancer drugs driving revenue, Syndax's upcoming Q2 report is a critical test of its path to profitability and ambitious pipeline.

A 76.5% approval rate seems acceptable, but new data reveals a fractured system where a patient's access to vital drugs is a lottery of delays and denials.

ADMA Biologics reported 20% growth, but a lawsuit alleges it was a sham built on channel stuffing and hidden deals. Here's what investors need to know.